Jim Cramer knows that many of the FANG faithful are tempted to sell. He makes the case as to why Facebook, Amazon, Netflix & Google could still surge.» Read More
The stock market could learn a lot from Swan, Ajax and the rest of the gang from the 1979 cult favorite "The Warriors."
Big investors are dismissing talk of a technology market peak given what they call unprecedented advances in the sector.
As if Twitter's stock didn't have enough problems, it now faces one more worry on the charts—a "death cross."
Cowen and Co.'s David Seaburg warns that the recent rally in the Chinese stock market could be too hot to touch.
Asia is the best bet for emerging markets for the next six months says UBS's Jorge Mariscal.
USA Today compiles eight stocks that have been consistent winners in S&P 500 over the last five years.
As a stock market analyst, Janet Yellen makes a pretty good Federal Reserve chair.
The leading private markets investor in the world still thinks that some bonds and loans are dangerously priced.
The Russell 2000 has crushed the S&P over the past month. Here's why traders continue to favor small caps.
Following its recent runup, the uptrend in WTI crude seems to be coming to an end, according to technical analysis by multiple research firms.
Some of the names on the move ahead of the open.
Consummate stock market bull Jeremy Siegel expects stocks to outperform following the Fed's anticipated interest rate hike.
Even beyond talk of a "June swoon," an unusual number of major events makes this month a critical time for markets.
Top tech investor Paul Meeks updates his "Squawk Box Platinum Portfolio" in these unexpected sectors.
CNBC's Fast Money team takes a look at five technology stocks that are set to fly higher.
Jim Cramer kicks off his healthcare hot list with one scorching name that does well in a slow growth economy.
The "Fast Money" traders give their final trades of the day.
Why it's time to strengthen your core portfolio.
Jim Cramer speaks to the CEO of Target on how he managed to turn around the business, and its new collaboration with Lilly Pulitzer.
RBC Capital Markets' Michael Yee said the selloff of Puma Biotech is in an overreaction and that the stock will represents an opportunity in the long run.